Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
36.61
+1.23 (3.48%)
At close: Aug 13, 2025, 4:00 PM
35.88
-0.73 (-1.99%)
After-hours: Aug 13, 2025, 6:56 PM EDT
Agios Pharmaceuticals Employees
As of December 31, 2024, Agios Pharmaceuticals had 488 total employees, including 486 full-time and 2 part-time employees. The number of employees increased by 102 or 26.42% compared to the previous year.
Employees
488
Change (1Y)
102
Growth (1Y)
26.42%
Revenue / Employee
$83,760
Profits / Employee
$1,332,137
Market Cap
2.13B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AGIO News
- 9 days ago - Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - GlobeNewsWire
- 13 days ago - Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Agios Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET - GlobeNewsWire
- 5 weeks ago - Agios Appoints Dr. Jay Backstrom to Board of Directors - GlobeNewsWire
- 2 months ago - Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders - Business Wire
- 2 months ago - Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 - GlobeNewsWire
- 3 months ago - Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress - GlobeNewsWire